The antiproliferative effects against these cell lines were more prominent than those against BCR-ABL-driven K562, a leukemic cell line derived from patients with CML in blastic phase reported to be susceptible to WP1130 [17,18]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.